Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002826 · ClinicalTrials.gov registry record · Phase 2
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00002826 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 36 participants.
The verdict
NCT00002826, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with a chemotherapy drug may reduce resistance to the drug, and allow the tumor cells to be killed. PURPOSE: Phase II trial to study the effectiveness of PSC 883 and paclitaxel in treating women who have recurrent or metastatic breast cancer.
Interventions
- DRUG paclitaxel
- DRUG valspodar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1997-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002826
The ClinicalTrials.gov registry entry for NCT00002826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00002826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002826 about?
NCT00002826 is a clinical study titled "Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer". RATIONALE: Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with a chemotherapy drug may reduce resistance to the drug, and allow the tumor cells to be killed. PURPOSE: Phase II trial to study the effectiveness of PSC 883 and paclitaxel in treating women who have recurrent or m...
What is the current status of trial NCT00002826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1997-08-14.
What interventions are being tested in trial NCT00002826?
The interventions under investigation include: paclitaxel (DRUG), valspodar (DRUG).
Who is sponsoring clinical trial NCT00002826?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.